目的 观察贝那普利联合左卡尼汀治疗扩张型心肌病心力衰竭的临床疗效。方法 选取2015年10月-2016年9月郑州市骨科医院收治的扩张型心肌病心力衰竭患者86例，随机分为对照组和治疗组，每组各43例。对照组患者静脉滴注左卡尼汀注射液，3 g/次，1次/d；治疗组在对照组的基础上口服盐酸贝那普利片，10 mg/次，1次/d。两组患者均治疗2周。评价两组患者临床疗效，同时比较治疗前后两组患者6 min步行距离、明尼苏达心力衰竭生活质量表评分（MLHFQ）、心脏彩超、高敏C反应蛋白（hs-CRP）和N末端B型钠尿肽原（NT-proBNP）水平改善情况。结果 治疗后，对照组和治疗组总有效率分别为76.74%、88.37%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者6 min步行距离明显增加，MLHFQ评分明显降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者6 min步行距离显著大于对照组，MLHFQ评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者LVESD和LVEDD均显著降低，LVEF显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组患者LVESD、LVEDD、LVEF改善程度均比对照组更明显（P<0.05）。治疗后，两组患者hs-CRP和NT-proBNP水平均显著降低（P<0.05）；且治疗后治疗组患者hs-CRP和NT-proBNP水平显著低于对照组（P<0.05）。结论 贝那普利联合左卡尼汀治疗扩张型心肌病心力衰竭效果明显，临床症状以及检查化验指标改善明显，不良反应较少，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of benazepril combined with levocarnitine in treatment of dilated cardiomyopathy heart failure. Methods Patients (86 cases) with dilated cardiomyopathy heart failure in Zhengzhou Orthopaedics Hospital from October 2015 to September 2016 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Levocarnitine Injection, 3 g/time, once daily. Patients in the treatment group were po administered with Benazepril Hydrochloride Tablets on the basis of the control group, 10 mg/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, clinical efficacy was evaluated, and the improvement of 6 min walking distance, MLHFQ scores, color Doppler ultrasound, hs-CRP, and NT-proBNP levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.74% and 88.37%, respectively, and there were differences between two groups (P<0.05). After treatment, the 6 min walking distance in two groups was significantly increased, but MLHFQ scores were significantly decreased, and the difference was statistically significant in the same group (P<0.05). The 6 min walking distance in the treatment group was significantly longer than that in the control group, and MLHFQ scores was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the LVESD and LVEDD in two groups were significantly decreased, but LVEF was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of LVESD, LVEDD, and LVEF in the treatment group was more significant than those in the control group, with significant difference between two groups (P<0.05). After treatment, the hs-CRP and NT-proBNP levles in two groups were significantly decreased (P<0.05). And the hs-CRP and NT-proBNP levels in treatment group were significantly lower than those in the control group (P<0.05). Conclusion Benazepril combined with levocarnitine has an obvious clinical curative effecst in treatment of dilated cardiomyopathy heart failure, clinical symptoms and laboratory examination indexes were significantly improved with less adverse reactions, which has a certain clinical application value.